• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

Hypertension

FDA approves Medtronic’s Symplicity Spyral renal denervation system

November 17, 2023 By Jim Hammerand

Medtronic today announced FDA approval of its Symplicity Spyral renal denervation (RDN) system for treating hypertension. [Update: Read more of our coverage from the weeks following the approval, including Medtronic’s lessons learned, what’s next for the technology, and other potential applications.] A Medtronic spokesperson said the device developer received word from regulators Friday evening. Medtronic […]

Filed Under: Cardiovascular, Catheters, Featured, Food & Drug Administration (FDA), News Well, Pre-Market Approval (PMA), Regulatory/Compliance Tagged With: FDA, Hypertension, Medtronic, RDN, renal denervation

ReCor Medical wins FDA panel nod for its renal denervation system

August 24, 2023 By Chris Newmarker

ReCor Medical announced that an FDA panel has voted in favor of the safety and efficacy of its Paradise ultrasound renal denervation (RDN) system for treating hypertension. On Aug. 22, the Circulatory Systems Devices Panel of the FDA’s Medical Devices Advisory Committee voted 12–0 in favor with regard to safety and 8–3 in favor, with […]

Filed Under: Cardiovascular, Catheters, Featured, Food & Drug Administration (FDA), News Well, Regulatory/Compliance Tagged With: Hypertension, ReCor Medical, renal denervation

Medtronic releases new renal denervation results, closes trial enrollment

April 4, 2022 By Jim Hammerand

Medtronic (NYSE:MDT) today said its Symplicity Spyral renal denervation (RDN) system demonstrated durable, clinically significant blood pressure reductions through three years for patients on medication. It’s the latest development out of Medtronic’s Spyral HTN-ON MED trial testing the company’s RDN catheter system, which delivers radiofrequency energy to overactive nerves near the kidneys that cause high blood pressure. […]

Filed Under: Blog, Cardiovascular, Catheters, Clinical Trials, Food & Drug Administration (FDA), News Well, Regulatory/Compliance Tagged With: FDA, Hypertension, Medtronic, renal denervation

MedtronicTalks: Why Symplicity Spyral trials are complicated, but worth it

December 2, 2021 By Tom Salemi

Medtronic’s campaign to secure FDA approval of its renal denervation device — Symplicity Spyral — has been anything but simple. But in this episode of the MedtronicTalks podcast, Jason Weidman, SVP and president of Coronary & Renal Denervation, explains why the company has refused to give up the fight to develop the renal denervation tool […]

Filed Under: Cardiovascular, Catheters, Device Talks Podcasts, Featured Tagged With: Hypertension, Medtronic, renal denervation

Medtronic builds suspense for renal denervation study results

September 10, 2021 By Jim Hammerand

Medtronic’s clinical study of its Symplicity Spyral renal denervation system for hypertension is likely to go down to the wire for inclusion as a late-breaking clinical trial at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) conference. The highly anticipated results will offer new insight into the Fridley, Minnesota-based medical device manufacturer’s quest to build a billion-dollar […]

Filed Under: Clinical Trials, Research & Development Tagged With: Hypertension, Medtronic, renal denervation

FDA approves Medtronic renal denervation trial in on-med patients

November 8, 2018 By Brad Perriello

Medtronic (NYSE:MDT) said today that the FDA approved a clinical trial of its Symplicity Spyral renal denervation device in patients who already take medication for their high blood pressure. Fridley, Minn.-based Medtronic said the three-year, 340-patient Spyral HTN-On Med sham-controlled study is designed to compare treatment with the Symplicity Spyral device and a sham procedure, randomized […]

Filed Under: Clinical Trials, Featured, Vascular Tagged With: Hypertension, Medtronic, Renal

Vascular Dynamics launches pivotal trial for MobiusHD hypertension device

September 5, 2018 By Brad Perriello

Vascular Dynamics said yesterday that it launched a pivotal trial of its MobiusHD device to treat high blood pressure ahead of a bid for a nod from the FDA. The MobiusHD device is designed to help regulate blood pressure by reshaping the the carotid artery to stimulate baroreceptors and increase the body’s natural response to lower blood […]

Filed Under: Cardiovascular, Clinical Trials Tagged With: Hypertension, vasculardynamics

Otsuka to acquire renal denervation firm ReCor Medical

July 10, 2018 By Brad Perriello

Otsuka Holdings (TYO:4578) said today that it plans to acquire the remaining stake it doesn’t already own in ReCor Medical and the renal denervation device it’s developing to treat hypertension. Tokyo-based Otsuka led ReCor’s $15 million Series D in April 2015 to back Palo Alto, Calif.- and Amsterdam-based ReCor’s Radiance-HTN study, which will test its Paradise system in patients […]

Filed Under: Mergers & Acquisitions, Ultrasound, Wall Street Beat Tagged With: Hypertension, Otsuka Holdings, ReCor Medical, Renal

ReCor Medical adds another $12m for trial of Paradise renal denervation device

August 16, 2017 By Brad Perriello

ReCor Medical last week added a $12 million contribution from Otsuka Pharmaceutical (TYO:4578) to the $10 million it raised from the Japanese conglomerate last year for a clinical trial of its Paradise renal denervation device for treating hypertension, ReCor president & CEO Andrew Weiss told MassDevice.com this morning. In May 2016 Otsuka participated in a strategic investment of an unspecified amount; […]

Filed Under: Clinical Trials, Funding Roundup, Wall Street Beat Tagged With: Hypertension, ReCor Medical

Vascular Dynamics raises $10m for MobiusHD

March 31, 2017 By Brad Perriello

Vascular Dynamics said this week that it closed a private placement worth $10.4 million that it plans to use on the clinical program for its MobiusHD device for treating drug-resistant hypertension. The MobiusHD implant is designed to reshape the carotid sinus to amplify the signals for baroreceptors lining the blood vessel. Implanted percutaneously, it’s designed to stimulate vasodilation. […]

Filed Under: Cardiovascular, Funding Roundup Tagged With: Hypertension, vasculardynamics

SteadyMed details commercialization plans for Trevyent

October 18, 2016 By Sarah Faulkner

SteadyMed Therapeutics (NSDQ:STDY) today detailed the development of its lead drug product candidate, Trevyent (treprostinil sodium), for the treatment of pulmonary arterial hypertension using its PatchPump tech at the Parenteral Drug Assn. Conference in Huntington Beach, Calif. PatchPump is the 1st single-use, wearable, pre-filled pump and treprostinil will be the 1st drug integrated with the delivery system, according to […]

Filed Under: Drug-Device Combinations, Research & Development Tagged With: Hypertension, SteadyMed Therapeutics

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 8
  • Go to Next Page »

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy